The contribution of common regulatory and protein-coding *TYR* variants in the genetic architecture of albinism

Vincent Michaud[1,2], Eulalie Lasseaux[1], David J. Green[3], Dave T. Gerrard,[3] Claudio Plaisant[1], UK Biobank Eye and Vision Consortium, Genomics England Research Consortium, Tomas Fitzgerald[4], Ewan Birney[4], Benoît Arveiler[1,2], Graeme C. Black[3,5], Panagiotis I. Sergouniotis[3,5,6]

[1] Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France.

[2] INSERM U1211, Rare Diseases, Genetics and Metabolism, University of Bordeaux, Bordeaux, France.

[3] Division of Evolution, Infection & Genomics, School of Biological Sciences, Faculty of Biology, Medicines and Health, University of Manchester, Manchester, UK.

[4] European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Cambridge, UK.

[5] Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

[6] Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

These authors contributed equally: VM, EL, DJG
These authors contributed equally: BA, GCB

ABSTRACT

Genetic diseases have been historically segregated into rare Mendelian and common complex conditions.[1,2] Large-scale studies using genome sequencing are eroding this distinction and are gradually unmasking the underlying complexity of human traits.[3–8] We studied a cohort of 1,313 individuals with albinism aiming to gain insights into the genetic architecture of rare, autosomal recessive disorders. We investigated the contribution of regulatory and protein-coding variants at the common and rare ends of the allele-frequency spectrum. We focused on *TYR,* the gene encoding tyrosinase, and found that a promoter variant, *TYR* c.-301C>T [rs4547091], modulates the penetrance of a prevalent, disease-associated missense change, *TYR* c.1205G>A [rs1126809]. We also found that homozygosity for a haplotype formed by three common, functional variants, *TYR* c.[-301C;575C>A;1205G>A], confers a high risk of albinism (OR>77) and is associated with reduced vision in UK Biobank participants. Finally, we report how the combined analysis of rare and common variants increases diagnostic yield and informs genetic counselling in families with albinism.

MAIN

There is abundant evidence supporting the view that rare genetic diseases are caused by rare, high-impact variants in individual genes. However, for virtually all known rare disorders, it is not possible to identify such pathogenic changes in every affected individual, leaving significant diagnostic and knowledge gaps.[9–11] In recent years, the emergence of comprehensive rare disease and population-based resources that link genomic and phenotypic data (e.g. UK Biobank[12], Genomics England 100,000 Genomes Project[13]) has offered unprecedented opportunities for genetic discovery. Through integrative analysis of the associated datasets, we can now achieve line-of-sight for uncovering complex molecular explanations in people with rare disorders who have hitherto remained undiagnosable.

Albinism, a rare condition characterised by decreased ocular pigmentation and altered visual system organisation[14], had a pivotal role in the study of human genetics tracing back to the early 20th century.[15,16] At least 20 genes are now known to be associated with this disorder and the current diagnostic yield of genetic testing in affected cohorts approaches 75%.[17–19] Most people with a molecular diagnosis of albinism carry biallelic variants in *TYR*, the gene encoding the rate-limiting enzyme of melanin biosynthesis[20]. Building on recent work[17,21], we sought to increase our understanding of the genetic complexity of this archetypal disorder.

A cohort of 1208 people with albinism underwent testing of ≤19 albinism-related genes; these individuals were not known to be related and had predominantly European ancestries. A further 105 probands with albinism were identified in the

Genomics England 100,000 Genomes Project dataset[13]. A "control" cohort of

29,497 unrelated individuals that had no recorded diagnosis/features of albinism

was also identified in this resource (Fig.1, Supplementary Table 1, Methods).

Figure 1. Outline of the case-control study design

100K_GP, Genomics England 100,000 Genomes Project; eQTLs, expression
quantitative trait loci; MAF, minor allele frequency; CADD, Combined Annotation
Dependent Depletion score; HGMD, Human Gene Mutation Database v2021.2.
TYR variant numbering is based on the transcript with the following identifiers:
NM_000372.5 and ENST00000263321.6.

To gain insights into the contribution of common variants to the genetic architecture

of albinism, we studied the impact of protein-coding changes that have minor allele

frequency [MAF] ≥1% and are predicted by a computational algorithm to be

functionally relevant (CADD score[22] ≥20). For *TYR*, two such variants were identified:

c.575C>A (p.Ser192Tyr) [rs1042602] and c.1205G>A (p.Arg402Gln) [rs1126809].

Multiple associations have been recorded for these two changes including skin/hair

pigmentation (for both variants), macular thickness (for c.575C>A) and iris colour

(for c.1205G>A).[23] Furthermore, each of these changes has been shown to decrease

TYR enzymatic activity *in vitro.*[24,25] Importantly, there is evidence suggesting that

c.1205G>A is acting as a hypomorphic variant and is causing a mild form of

albinism when in compound heterozygous state with a complete loss-of-function

TYR mutation.[26] However, the MAF of this variant in European populations is around

27% and multiple unaffected homozygous individuals have been reported (including

>2,000 people in the control subset of the Genome Aggregation Database

[gnomAD] v2.1.1)[27].

To gain insights into the contribution of regulatory variants, we studied the impact of

changes that alter *TYR* regulatory elements (*i.e.* the *TYR* promoter or ENCODE-

listed enhancers)[28] and affect *TYR* gene expression (*i.e.* they are known *TYR*

expression quantitative trait loci [*eQTL*]). One such variant was identified, c.-301C>T

[rs4547091], a fetal retinal pigment epithelium (RPE) selective eQTL[29]. This change is

known to alter a binding site for the transcription factor *OTX2* in the *TYR* promoter,

and the reference allele (c.-301C) has been shown to lead to a remarkable decrease

in promoter activity *in vitro*[30].

Focusing on individual sequence alterations without consideration for variant

interactions and/or patterns of linkage disequilibrium can lead to masking of

complex underlying mechanisms. To overcome this pitfall, we avoided an

independent analysis of each of the *TYR* c.-301C>T, c.575C>A and c.1205G>A

changes and instead studied the haplotype blocks that they form. Eight possible

haplotypes [2^3] and 36 possible haplotype pairs [2^{3-1} x (2^3+1)] may be encountered.

We focused only on the 8 haplotype pairs that include homozygous alleles (Fig.2A)

for two reasons: (1) in homozygous individuals, the underlying haplotypes can be

unambiguously determined, even in cases where segregation/phasing data are

unavailable; (2) in autosomal recessive disorders like *TYR*-associated albinism,

phenotypic abnormalities are the result of the combined effect of two alleles; by

analyzing only homozygous cases, the effect of a specific haplotype can be isolated

and estimated with greater precision.

We used Firth regression analysis[31,32] to study how *TYR* haplotypes in homozygous

state affect the risk of albinism. This increasingly recognised logistic regression

approach has been designed to handle small, imbalanced datasets (which are

common in studies of rare conditions) and allows for adjustment of key covariates

(which is not possible in contingency table methods) (Fig.1, Methods). The results

are shown in Fig.2B and Supplementary Table 2. This analysis identified a number

of pertinent points that are discussed below.

Figure 2. Common *TYR* variants form haplotypes that affect risk of albinism and visual performance.

a. The *TYR* haplotypes that were studied are shown. The reference allele of the *TYR* c.-301C>T [rs4547091] promoter variant reduces gene expression and is shown as C (↓); the non-reference allele increases gene expression and is shown as T (↑). The reference alleles of the c.575C>A (p.Ser192Tyr) [rs1042602] and c.1205G>A (p.Arg402Gln) [rs1126809] missense variants are highlighted in green font while the non-reference alleles are highlighted in red font. As no homozygotes for the *TYR* [-301T;575A;1205A] and [-301T;575A;1205G] haplotypes were detected, these combinations are highlighted in grey font.

b. Risk of albinism in people carrying selected *TYR* haplotypes in homozygous state. Odds ratio >1 suggests an increased risk while odds ratio <1 suggests a decreased risk. Further information including numeric data can be found in Supplementary Table 2.

c. Visual acuity in UK Biobank participants carrying selected *TYR* haplotypes in homozygous state. Vision near 0.0 LogMAR is considered normal while vision >0.5 LogMAR is considered moderate/severe visual impairment. The Kruskal-Wallis p-value was 8×10^{-11}. Further information including numeric data can be found in Supplementary Table 4.

We found that the penetrance of the hypomorphic *TYR* c.1205G>A variant[26] is modulated by the *TYR* c.-301C>T promoter change. When c.1205G>A is encountered in a homozygous state and in combination with the c.-301C allele of the promoter variant (which reduces *TYR* expression), the risk of albinism is high (OR>19; see [C;A;A] and [C;C;A] in Fig.2B). In contrast, homozygosity for

c.1205G>A combined with the c.-301T allele (which increases *TYR* expression) has a protective effect (OR<0.6; see [T;C;A] in Fig.2B). This observation is in keeping with previous studies suggesting that penetrance can be modified by the joint functional effects of regulatory and protein-coding variants.[33] We here provide a key illustration of this mechanism in the context of a recessively-acting hypomorphic variant.

Alongside this, we found that homozygosity for the *TYR* c.-301C>T promoter variant protects against albinism (OR 0.2-0.7; see [T;C;A] and [T;C;G] in Fig.2B). Notably, the allele frequency of the protective c.-301T allele, approaches 80% in people of African ancestries and is around 40% in people of European ancestries[27] (see Supplementary Fig.1 for the geographical distribution of the associated variants/haplotypes). It can be speculated that variation in this *TYR* promoter position partly accounts for the relatively low prevalence of *TYR*-associated albinism in people of African ancestries (Supplementary Table 3).

Our findings also highlight that homozygosity for the haplotype formed by the c.-301C allele of the promoter variant (which reduces *TYR* expression) and the non-reference alleles of the two common missense changes, c.575C>A and c.1205G>A, is associated with a significant increase in the risk of albinism (OR >77; see [C;A;A] in Fig.2B). This haplotype is present in ~1% of people with European ancestries in the 1000 Genomes Project (phase 3)[34], and the associated risk of albinism is comparable to that of a loss-of-function Mendelian mutation.

When the *TYR* c.[-301C;575A;1205A] and c.[-301C;575C;1205A] haplotypes (corresponding to [C;A;A] and [C;C;A] in Fig.2B) were factored in as Mendelian variants in a clinical-grade analysis of the case cohort, the diagnostic yield increased from 57% (693/1208) to 76% (920/1208). Current genetic laboratory pipelines are generally suboptimally set up to identify these complex high-risk haplotypes, especially when filtering is based on the rarity of individual variants.

We subsequently studied the impact of the *TYR* c.[-301C;575A;1205A] haplotype (corresponding to [C;A;A] in Fig.2B) in UK Biobank participants. We found that people who were homozygous for this haplotype had, on average, reduced visual acuity (mean LogMAR vision 0.10; Kruskal-Wallis p-value 8×10^{-11} with all pair-wise comparisons involving [C;A;A] being statistically significant; Fig.2C and Supplementary Table 4). As visual acuity is a quantitative endophenotype of albinism, this finding provides additional evidence supporting the functional significance of this complex haplotype. A similar trend was noted when central retinal thickness, another albinism endophenotype, was assessed (Kruskal-Wallis p-value $< 2 \times 10^{-16}$; Supplementary Fig.2 and Supplementary Table 5). We expect that future studies of visual function and ocular structure in this group of homozygous individuals will provide key insights into the elusive link between RPE melanin synthesis and visual system organisation.[35]

Finally, we quantified the risk of albinism associated with combinations of rare and common variants. For each study participant, we estimated two key contributors to an individual's risk. First, we counted the number of rare, presumed Mendelian

variants in albinism-associated genes; single nucleotide variants that have MAF<1% and are labelled as disease-causing (DM) in the Human Gene Mutation Database (HGMD) v2021.2[36] were considered. Subsequently, we counted the number of common "risk genotypes" in *TYR* (*i.e.* c.-301C, c.575A and/or c.1205A). We found that the presence of >4 common *TYR* risk genotypes confers an increased risk of albinism even in the absence of a rare, HGMD-listed variant (OR>4; Table 1). We also found that when a single heterozygous HGMD-listed variant co-occurs with >1 common *TYR* risk genotype, the risk of albinism is increased (OR>4 for rare variants in any albinism-related gene, OR>6 for rare variants in *TYR;* Table 1). These observations provide a basis for more precise genetic counseling in families with albinism.

In conclusion, we have shown that a significant proportion of albinism risk arises from genetic susceptibility linked to common variants. Our findings also suggest that rare and common protein-coding variation in *TYR* should be considered in the context of regulatory haplotypes. The concepts discussed here are highly likely to be relevant to the understanding of other rare disorders, and haplotype-based approaches are expected to narrow the diagnostic gap for significant numbers of patients. Future work will embrace more diverse populations and focus on integrating both common and rare variants (including single-nucleotide and copy-number changes) into a single genetic risk score at scale.

METHODS

Cohort characteristics and genotyping

University Hospital of Bordeaux albinism cohort: Individuals with albinism were identified through the database of the University Hospital of Bordeaux Molecular Genetics Laboratory, France. This is a national reference laboratory that has been performing genetic testing for albinism since 2003 and has been receiving samples from individuals predominantly based in France (or French-administered overseas territories). Information on the dermatological and ophthalmological phenotypes was available and all people included in the study had at least one of the key ocular features of albinism, *i.e.* nystagmus or absence of a foveal pit (prominent foveal hypoplasia). Only individuals who were not knowingly related were included.

Genotyping, bioinformatic analyses, and clinical interpretation were performed as previously described.[17,26] Briefly, most participants had gene-panel testing of 19 genes associated with albinism (*TYR*, *OCA2*, *TYRP1*, *SLC45A2*, *SLC24A5*, *C10ORF11*, *GPR143*, *HPS 1* to 10, *LYST*, *SLC38A8*) using IonTorrent platforms. High-resolution array-CGH (comparative genomic hybridization) was also used to detect copy number variants in these 19 genes. All genetic changes of interest were confirmed with an alternative method (e.g. Sanger sequencing or quantitative PCR). Clinical interpretation of variants was performed using criteria consistent with the 2015 American College of Medical Genetics and Genomics (ACMG) best practice guidelines[37]. Generally, variants with MAF ≥1% in large publicly available datasets (e.g. gnomAD[27]) were considered unlikely to be disease-causing. We note that the genetic findings in a subset of this cohort (70%; 845/1208) have been partly reported in a previous publication.[17]

Due to the limited number of genes screened in this cohort, it was not possible to reliably assess genetic ancestry and to objectively assign individuals to ancestry groups. Attempting to mitigate this, we processed available data on self-identified ethnicity that were collected through questionnaires. Responses were inspected and stratification into five broad continental groups (European, African, Admixed American, East Asian, South Asian) was performed.

Informed consent was obtained from all participants or their parents in the case of minors. The study was approved by the relevant local ethics committee (Comité de Protection des Personnes Sud-Ouest et Outre Mer III, Bordeaux, France) and all investigations were conducted in accordance with the tenets of the Declaration of Helsinki.

Genomics England 100,000 Genomes Project cohort: Clinical and genomic data from the Genomics England 100,000 Genomes Project were accessed through a secure Research Environment that is available to registered users (further information on this can be found online at https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-access). This dataset was collected as part of a national genome sequencing initiative.[38] Enrolment was coordinated by Genomics England Limited and participants were recruited mainly at National Health Service (NHS) Hospitals in the UK.[13] Clinical information was recorded in Human Phenotype Ontology (HPO)[39] terms and International Classification of Diseases (ICD) codes. Genome sequencing was performed in DNA samples from 78,195 individuals using Illumina HiSeq X systems (150 base-pair paired-end format). Reads were aligned using the iSAAC Aligner v03.16.02.19 and small variants were called using Starling v2.4.7.[40] Aggregation of single-sample gVCFs was performed using the Illumina software gVCF genotyper v2019.02.29; normalisation/decomposition was implemented by vt version 0.57721[41]. The multi-sample VCF was then split into 1,371 roughly equal chunks to allow faster processing and the loci of interest were queried using bcftools v1.9[42] (see https://research-help.genomicsengland.co.uk/display/GERE/ for further information). Only variants that passed all provided site quality control criteria were processed. In addition, we filtered out genotypes with: genotype score <20; read depth <10; allele balance <0.2 and >0.8 for heterozygotes; allele balance >0.1 or <0.9 for homozygotes (reference and alternate, respectively). Genomic annotation was performed using Ensembl VEP[43]; one additional annotation was included - presence of a variant in HGMD v2021.2[36] with a "disease-causing" (DM) label.

Ancestry inference was performed in this cohort using principal component analysis. Data from the 1000 genomes project (phase 3) dataset[38] was used and five broad super-populations were projected (European, African, Admixed American, East Asian, South Asian) (further information on

this can be found online at https://research-

help.genomicsengland.co.uk/display/GERE/Ancestry+inference).

We focused on a pre-determined subset of the Genomics England 100,000 Genomes Project

dataset that includes only unrelated probands (n=29,602). 105 of these individuals had a diagnosis of

albinism, *i.e.* the ICD-10 term "Albinism" [E70.3] and/or the HPO terms "Albinism" [HP:0001022],

"Partial albinism" [HP:0007443] or "Ocular albinism" [HP:0001107] were assigned. Together with the

University Hospital of Bordeaux cases, these 105 probands formed the "case" cohort (for the

albinism risk analysis). The remaining 29,497 probands had no recorded diagnosis or phenotypic

features of albinism and formed the "control" cohort.

Identifying functional regulatory and protein-coding variants

Regulatory variants: Focusing on *TYR*, we identified changes that are likely to have an impact on

gene regulation by selecting variants that:

- are known *TYR* eQTLs.

- alter *TYR* cis-regulatory elements, including the promoter of the gene.

To identify eQTLs, we inspected the eQTL catalogue[44] and used data from the Genotype-Tissue

Expression v8 (GTEx)[45] and Eye Genotype Expression (EyeGEx)[46] projects. To identify regulatory

elements, we used the ENCODE 3 (ENCyclopedia Of DNA Elements phase 3) dataset[28] and

inspected chromatin accessibility peaks in RPE samples in DESCARTES (the Developmental Single

Cell Atlas of Gene Regulation and Expression)[47]. Extensive search of the biomedical literature (e.g.[29])

was also performed. All these queries were conducted in January 2021.

Common protein-coding variants: Focusing on *TYR*, we identified common changes that are likely to

have an impact on protein function by selecting variants that:

- have a CADD PHRED-scaled score ≥20. CADD is an integrative annotation tool built from more

   than 60 genomic features. A PHRED-scaled score ≥10 indicates a raw score in the top 10% of

   all possible single nucleotide variants, while a score ≥20 indicates a raw score in the top 1%.[22]

- alter protein-coding sequences - including missense changes, nonsense variants and small insertions/deletions; variants with a potential role on splicing (e.g. synonymous changes and variants altering splice donor/acceptor sites) were not included.

- have "total" MAF ≥1% in gnomAD v2.1.1[27]

Rare protein-coding variants: Focusing on 19 albinism-related genes *(TYR, OCA2, TYRP1, SLC45A2, SLC24A5, C10ORF11, GPR143, HPS 1 to 10, LYST, SLC38A8)*, we identified rare changes that are likely to have an impact on protein function by selecting variants that:

- are labelled as disease-causing (DM) in HGMD v2021.2.

- are included in the following HGMD v2021.2 "mutation type" categories: missense/nonsense, splicing, small deletions, small insertions or small indels; gross deletions, gross insertions/duplications and complex rearrangements were not analysed.

- have "total" MAF <1% in gnomAD v2.1.1[27].

Case-control analysis to estimate albinism risk

The effect of homozygosity for selected *TYR* haplotypes (formed by one common regulatory change, c.-301C>T, and two common protein-coding variants, c.575C>A and c.1205G>A variants) on albinism risk was estimated using data from the University Hospital of Bordeaux albinism cohort and the Genomics England 100,000 Genomes Project dataset. A case-control analysis of a binary trait (presence/absence of albinism) was conducted assuming a recessive model. There was case-control imbalance and the two cohorts were imperfectly matched, especially in terms of genetic ancestry and genotyping approach used. These sources of bias should be taken into account when interpreting the results, especially findings with low-effect and/or low-confidence signal.

Logistic regression using Firth's bias reduction method[31,32] was used (as implemented in "logistf" R package)[50]. The following covariates were included: gender, number of rare HGMD-listed variants and ancestry (Supplementary Table 2).

Analysis of visual acuity and foveal thickness in UK Biobank participants

The effect of homozygosity for selected *TYR* haplotypes was studied in UK Biobank participants. UK Biobank is a biomedical resource containing in-depth genetic and health information from >500,000 individuals from across the UK[12]. A subset of UK Biobank volunteers underwent enhanced phenotyping including visual acuity testing (131,985 individuals) and imaging of the central retina (84,748 individuals)[48]; the latter was obtained using optical coherence tomography (OCT), a non-invasive imaging test that rapidly generates cross-sectional retinal scans at micrometre-resolution.[49] Notably, only 24 UK Biobank participants are assigned a diagnosis of albinism (data field 41270; ICD-10 term "Albinism" [E70.3]) of which only 7 had visual acuity measurements and none had OCT imaging. Given that reduced visual acuity and increased central retinal thickness (due to underdevelopment of the fovea) are two key hallmark features of albinism we investigated the impact of *TYR* risk haplotypes on these quantitative endophenotypes.

First, genotyping array data were used to obtain genotypes for *TYR* c.575C>A [rs1042602] and *TYR* c.1205G>A [rs1126809] (data field 22418 including information from the Applied Biosystems UK Biobank Axiom Array containing 825,927 markers). In contrast to these two changes, the *TYR* c.-301C>T [rs4547091] variant was not directly captured by the array. However, high-quality (>99.9%) imputation data on this promoter change were available (data field 22828).

Subsequently, we calculated the mean of the right and left LogMAR visual acuity for each UK Biobank volunteer (data fields 5201 and 5208, "instance 0" datasets). These visual acuity measurements were subsequently used to compare visual performance between groups of people with different homozygous haplotype combinations. As the obtained distributions deviated from normality (Fig.2C), the Kruskal-Wallis test was used. Pair-wise comparisons were performed and the p-values were adjusted using the Benjamini-Hochberg method (Supplementary Table 4).

To obtain central foveal thickness measurements from UK Biobank OCT images, we calculated the mean of the right and left central retinal thickness (defined as the average distance between the hyperreflective bands corresponding to the RPE and the internal limiting membrane (ILM), across the central 1 mm diameter circle of the ETDRS grid) for each UK Biobank volunteer).[51] The obtained measurements were then subsequently used to compare central macular thickness between groups

of UK Biobank volunteers with different homozygous *TYR* haplotype combinations. As some of the obtained distributions deviated from normality (Supplementary Fig.2), the Kruskal-Wallis test was used. Pair-wise comparisons were performed and the p-values were adjusted using the Benjamini-Hochberg method (Supplementary Table 5).

ACKNOWLEDGEMENTS

We acknowledge the following sources of funding: the Wellcome Trust (200990/Z/16/Z, Transforming Genetic Medicine Initiative); Christopher Green; Retina UK and Fight for Sight (GR586, RP Genome Project - UK Inherited Retinal Disease Consortium); Health Education England; UK National Institute for Health Research (NIHR) Clinical Lecturer Programme (CL-2017-06-001); the French Albinism Association (Genespoir).

This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support.

This research was conducted using the UK Biobank Resource under projects 53144, 49978 and 2112.

The authors acknowledge the help of Cécile Courdier at the University Hospital of Bordeaux Molecular Genetics Laboratory.

Genomics England Research Consortium: John C. Ambrose, Prabhu Arumugam, Roel Bevers, Marta Bleda, Freya Boardman-Pretty, Christopher R. Boustred, Helen Brittain, Mark J. Caulfield, Georgia C. Chan, Greg Elgar, Tom Fowler, Adam Giess, Angela Hamblin, Shirley Henderson, Tim J. P. Hubbard, Rob Jackson, Louise J. Jones, Dalia Kasperaviciute, Melis Kayikci, Athanasios Kousathanas, Lea Lahnstein, Sarah E. A. Leigh, Ivonne U. S. Leong, Javier F. Lopez, Fiona Maleady-Crowe, Meriel McEntagart, Federico Minneci, Loukas Moutsianas, Michael Mueller, Nirupa Murugaesu, Anna C. Need, Peter O'Donovan, Chris A. Odhams, Christine Patch, Mariana Buongermino Pereira, Daniel Perez-Gil, John Pullinger, Tahrima Rahim, Augusto Rendon, Tim Rogers, Kevin Savage, Kushmita Sawant, Richard H. Scott, Afshan Siddiq, Alexander Sieghart, Samuel C. Smith, Alona Sosinsky, Alexander Stuckey, Mélanie Tanguy, Ana Lisa Taylor Tavares, Ellen R. A. Thomas, Simon R. Thompson, Arianna Tucci, Matthew J. Welland, Eleanor Williams, Katarzyna Witkowska, Suzanne M. Wood

UK Biobank Eye and Vision Consortium: Tariq Aslam, Sarah Barman, Jenny Barrett, Paul Bishop, Catey Bunce, Roxana Carare, Usha Chakravarthy, Michelle Chan, Valentina Cipriani, Alexander Day, Parul Desai, Bal Dhillon, Andrew Dick, Cathy Egan, Sarah Ennis, Paul Foster, Marcus Fruttiger, John Gallacher, David Garway-Heath, Jane Gibson, Dan Gore, Jeremy Guggenheim, Chris Hammond, Alison Hardcastle, Simon Harding, Ruth Hogg, Pirro Hysi, Pearse A. Keane, Peng T. Khaw, Anthony Khawaja, Gerassimos Lascaratos, Andrew J. Lotery, Phil Luthert, Tom Macgillivray, Sarah Mackie, Bernadette Mcguinness, Gareth Mckay, Martin Mckibbin, Danny Mitry, Tony Moore, James Morgan, Zaynah Muthy, Eoin O'Sullivan, Chris Owen, Praveen Patel, Euan Paterson, Tunde Peto, Axel Petzold, Jugnoo Rahi, Alicja Rudnicka, Jay Self, Sobha Sivaprasad, David Steel, Irene Stratton, Nicholas Strouthidis, Cathie Sudlow, Caroline Thaung, Dhanes Thomas, Emanuele Trucco, Adnan Tufail, Veronique Vitart, Stephen Vernon, Ananth Viswanathan, Cathy Williams, Katie Williams, Jayne Woodside, Max Yates, Jennifer Yip, Yalin Zheng, Robyn Tapp, Denize Atan, Alexander Doney, Naomi Allen, Thomas Littlejohns, Panagiotis Sergouniotis, Graeme Black

REFERENCES

1.   Claussnitzer, M. *et al.* A brief history of human disease genetics. *Nature* **577**, 179–189 (2020).

2.   Shendure, J., Findlay, G. M. & Snyder, M. W. Genomic Medicine–Progress, Pitfalls, and Promise. *Cell* **177**, 45–57 (2019).

3.   Niemi, M. E. K. *et al.* Common genetic variants contribute to risk of rare severe neurodevelopmental disorders. *Nature* **562**, 268–271 (2018).

4.   Tilghman, J. M. *et al.* Molecular genetic anatomy and risk profile of Hirschsprung's disease. *N. Engl. J. Med.* **380**, 1421–1432 (2019).

5.   Turro, E. *et al.* Whole-genome sequencing of patients with rare diseases in a nationalhealth system. *Nature* **583**, 96 (2020).

6.   Chung, B. H. Y., Chau, J. F. T. & Wong, G. K.-S. Rare versus common diseases: a false dichotomy in precision medicine. *NPJ genomic Med.* **6**, (2021).

7.   Khan, M. *et al.* Resolving the dark matter of ABCA4 for 1054 Stargardt disease probands through integrated genomics and transcriptomics. *Genet. Med.* **22**, 1235–1246 (2020).

8.   Harper, A. R. *et al.* Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. *Nat. Genet. 2021 532* **53**, 135–142 (2021).

9.   Boycott, K. M. *et al.* International cooperation to enable the diagnosis of all rare genetic diseases. *Am. J. Hum. Genet.* **100**, 695 (2017).

10.   Ferreira, C. R. The burden of rare diseases. *Am. J. Med. Genet. A* **179**, 885–892 (2019).

11.   Chakravarti, A. Magnitude of Mendelian versus complex inheritance of rare disorders. *Am. J. Med. Genet. A* (2021). doi:10.1002/AJMG.A.62463

12.   Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).

13.   Genomics England. The National Genomic Research Library v5.1. (2019). Available at: https://doi.org/10.6084/m9.figshare.4530893.v6.

14.   Kruijt, C. C. *et al.* The phenotypic spectrum of albinism. *Ophthalmology* **125**, 1953–1960 (2018).

15.   Farabee, W. C. Notes on Negro Albinism. *Science* **17**, 75 (1903).

16.   Garrod, A. E. The Croonian Lectures on Inborn Errors of Metabolism. *Lancet* **172**, 1–7 (1908).

17.   Lasseaux, E. *et al.* Molecular characterization of a series of 990 index patients with albinism. *Pigment Cell Melanoma Res.* **31**, 466–474 (2018).

18.   Wang, C. *et al.* [Spectrum of pathological genetic variants among 405 Chinese pedigrees

affected with oculocutaneous albinism]. *Chin J Med Genet* **37**, 725–730 (2020).

19. Mauri, L. *et al.* Clinical evaluation and molecular screening of a large consecutive series of albino patients. *J. Hum. Genet.* **62**, 277–290 (2017).

20. Pavan, W. J. & Sturm, R. A. The genetics of human skin and hair pigmentation. *Annu. Rev. Genomics Hum. Genet.* **20**, 41–72 (2019).

21. Campbell, P. *et al.* Clinical and genetic variability in children with partial albinism. *Sci. Rep.* **9**, 16576 (2019).

22. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: Predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* **47**, D886–D894 (2019).

23. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **47**, D1005 (2019).

24. Chaki, M. *et al.* Molecular and functional studies of tyrosinase variants among Indian oculocutaneous albinism type 1 patients. *J. Invest. Dermatol.* **131**, 260–262 (2011).

25. Jagirdar, K. *et al.* Molecular analysis of common polymorphisms within the human Tyrosinase locus and genetic association with pigmentation traits. *Pigment Cell Melanoma Res.* **27**, 552–564 (2014).

26. Monfermé, S. *et al.* Mild form of oculocutaneous albinism type 1: phenotypic analysis of compound heterozygous patients with the R402Q variant of the TYR gene. *Br. J. Ophthalmol.* **103**, 1239–1247 (2019).

27. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443 (2020).

28. The ENCODE Project Consortium *et al.* Expanded encyclopaedias of DNA elements in the human and mouse genomes. *Nature* **583**, 699–710 (2020).

29. Liu, B. *et al.* Genetic analyses of human fetal retinal pigment epithelium gene expression suggest ocular disease mechanisms. *Commun. Biol.* **2**, 186 (2019).

30. Reinisalo, M., Putula, J., Mannermaa, E., Urtti, A. & Honkakoski, P. Regulation of the human tyrosinase gene in retinal pigment epithelium cells: The significance of transcription factor orthodenticle homeobox 2 and its polymorphic binding site. *Mol. Vis.* **18**, 38–54 (2012).

31. Heinze, G. & Schemper, M. A solution to the problem of separation in logistic regression. *Stat. Med.* **21**, 2409–2419 (2002).

32. Firth, D. Bias Reduction of Maximum Likelihood Estimates. *Biometrika* **80**, 27 (1993).

33. Castel, S. E. *et al.* Modified penetrance of coding variants by cis-regulatory variation contributes to disease risk. *Nat. Genet.* **50**, 1327 (2018).

34. Auton, A. *et al.* A global reference for human genetic variation. *Nat. 2015 5267571* **526**, 68–74 (2015).

35.   Mason, C. & Guillery, R. Conversations with Ray Guillery on albinism: linking Siamese cat visual pathway connectivity to mouse retinal development. *Eur. J. Neurosci.* **49**, 913–927 (2019).

36.   Stenson, P. D. *et al.* The Human Gene Mutation Database (HGMD ®): optimizing its use in a clinical diagnostic or research setting. *Hum. Genet.* **139**, 1197–1207 (2020).

37.   Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med. 2015 175* **17**, 405–423 (2015).

38.   Turnbull, C. *et al.* The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. *BMJ* **361**, 1687 (2018).

39.   Köhler, S. *et al.* The Human Phenotype Ontology in 2021. *Nucleic Acids Res.* **49**, D1207–D1217 (2021).

40.   Raczy, C. *et al.* Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms. *Bioinformatics* **29**, 2041–2043 (2013).

41.   Tan, A., Abecasis, G. R. & Kang, H. M. Unified representation of genetic variants. *Bioinformatics* **31**, 2202–2204 (2015).

42.   Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, giab008 (2021).

43.   McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, (2016).

44.   Nurlan, K. *et al.* A compendium of uniformly processed human gene expression and splicing quantitative trait loci. *Nat. Genet.* **53**, 1290–1299 (2021).

45.   The GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* **369**, 1318–1330 (2020).

46.   Ratnapriya, R. *et al.* Retinal transcriptome and eQTL analyses identify genes associated with age-related macular degeneration. *Nat. Genet.* **51**, 606–610 (2019).

47.   Domcke, S. *et al.* A human cell atlas of fetal chromatin accessibility. *Science* **370**, (2020).

48.   Chua, S. Y. L. *et al.* Cohort profile: design and methods in the eye and vision consortium of UK Biobank. *BMJ Open* **9**, e025077 (2019).

49.   Drexler, W. & Fujimoto, J. G. State-of-the-art retinal optical coherence tomography. *Prog. Retin. Eye Res.* **27**, 45–88 (2008).

50.   Heinze, G., Ploner, M., Dunkler, D., Soutworth, H. & Jiricka, L. logistf: Firth's bias-reduced logistic regression R package v1.24 (2020).

51.   Patel, P. J. *et al*. Spectral-domain optical coherence tomography imaging in 67,321 adults: associations with macular thickness in the UK Biobank study. Ophthalmology **123**, 829-840 (2016).

TABLE

Table 1. Contribution of different classes of albinism-associated variants to disease risk

combination of common [a] and rare [b] risk genotypes	odds ratio [c]	95% confidence interval	unadjusted p-value
6 common + 0 rare	393	163 - 949	<0.00001
5 common + 0 rare	7.8	4.0 - 16.6	<0.00001
4 common + 0 rare	3.4	1.9 - 5.9	<0.00001
3 common + 0 rare	1.5	0.8 - 2.6	0.10
2 common + 0 rare	2.2	1.3 - 3.8	0.02
1 common + 0 rare	1.1	0.6 - 1.9	0.80
0 common + 0 rare	0.1	0.1 - 0.2	<0.00001
6 common + 1 rare [d]	220	20 - 2418	0.00001
5 common + 1 rare	298	156 - 566	<0.00001
4 common + 1 rare	38	22 - 66	<0.00001
3 common + 1 rare	8.7	4.9 - 15.4	<0.00001
2 common + 1 rare	7.5	4.1 - 13.0	<0.00001
1 common + 1 rare	5.9	3.2 - 11.0	<0.00001
0 common + 1 rare	2.5	1.2 - 5.3	0.01
0 common + 2 rare	155	70 - 340	<0.00001
6 common + 1 rare *TYR* [d]	636	7 - 60169	0.005
5 common + 1 rare *TYR*	965	467 - 1992	<0.00001
4 common + 1 rare *TYR*	208	119 - 362	<0.00001
3 common + 1 rare *TYR*	28.8	15.5 – 53.5	<0.00001
2 common + 1 rare *TYR*	12.8	6.6 - 24.6	<0.00001
1 common + 1 rare *TYR* [d]	2.9	0.9 - 9.2	0.07
0 common + 1 rare *TYR* [d]	6.4	1.5 – 27.3	0.01
0 common + 2 rare *TYR* [d]	1422	347 - 5828	<0.00001

[a] presence of each of the following *TYR* variants in heterozygous state was considered as one common risk genotype: c.-301C [rs4547091]; c.575C>A (p.Ser192Tyr) [rs1042602]; c.1205G>A (p.Arg402Gln) [rs1126809]. *TYR* variant numbering is based on the transcript with the following identifiers: NM_000372.5 and ENST00000263321.6.

[b] autosomal albinism-associated genes were inspected and each heterozygous protein-coding change with a minor-allele frequency <1% and a "disease-causing" (DM) label in the Human Gene Mutation Database (HGMD) v2021.2 was considered as one rare risk genotype. Such genotypes in the *TYR* gene are labelled "*rare TYR*".

[c] Firth regression analysis with gender and ancestry as covariates was used to estimate odds ratios and p-values; 1,121 probands with albinism and 29,453 unrelated controls were included.

[d] Less than 10 individuals were included in the smallest subgroup of these categories, reducing the reliability of the associated findings.